| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study is to clarify the molecular target of Trim32-based differentiation therapy for neuroblastoma cells and to establish a new treatment method of neuroblastoma by a novel mechanism. We attempted to identify new target gene (s) in Trim32-mediated cell differentiation by cDNA microarray. As a result of analysis by cDNA microarray, CDKN1A was identified as a gene whose expression increased in Trim32-mediated cell differentiation. When CDKN1A is knocked down in human neuroblastoma cells, 13-cis-retinoid (13-cis) mediated cell differentiation ability decreased. Furthermore, when 13-cis treatment is performed on human neuroblastoma cells after transfection of CDKN1A cDNA expression vector, the differentiation inducing ability significantly increased.
|
